US Appeal Against 2021 Cabazitaxel Patent Falls Flat
An attempt by Accord, Actavis, Apotex, Kabi and Mylan to overturn a US patent protecting Sanofi’s Jevtana cabazitaxel cancer drug until 2021 has failed. And claims in a patent running until 2031 could yet return to haunt the generics firms.
You may also be interested in...
In the month ahead, Alvogen’s biosimilars sister company Alvotech is anticipated to receive a USFDA decision on its biosimilar Humira candidate, while Hikma’s management will meet investors to discuss prospects for its Generics business.
A US Court of Appeals has dealt a blow to Mylan by restoring parts of a patent that protects Sanofi’s Jevtana cancer treatment until 2031.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.